AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4769-4775

  Davies, Nicholas J ^a   Hayden, Rachel E ^a   Simpson, Paul J ^a   Birtwistle, Jane ^a   Mayer, Katarina ^a   Ride, Jonathan P ^a   Bunce, Chris M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JASMONIC ACID; JASMONIC ACID METHYL ESTER; OXIDOREDUCTASE; PROSTAGLANDIN SYNTHASE; PROTEIN AKR1C; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

20-HYDROXYSTEROID DEHYDROGENASES; ACETIC ACIDS; CELL SURVIVAL; CELLS, CULTURED; CYCLOPENTANES; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; ISOENZYMES; LEUKEMIA, MYELOID; MITOCHONDRIA; MODELS, BIOLOGICAL; OXYLIPINS; PROSTAGLANDIN D2; REACTIVE OXYGEN SPECIES;

EID: 66349108684     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4533     Document Type: Article

References (49)

1. Lan Q, Mumford JL, Shen M, et al. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004;25:2177-2181 (Pubitemid 39539183)
2. Cunningham JM, Hebbring SJ, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:969-978 (Pubitemid 46910099)
3. Figueroa JD, Malats N, Garcia-Closas M, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008;29:1955-1962
4. Lan Q, Zheng T, Shen M, et al. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet 2007;121:161-168 (Pubitemid 46404450)
5. Liu CY, Hsu YH, Pan PC, et al. Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia. Carcinogenesis 2008;29:984-990
6. Novotna R, Wsol V, Xiong G, Maser E. Inactivation of the anticancer drugs doxorubicin and oracin by aldoketo reductase (AKR) 1C3. Toxicol Lett 2008;181:1-6.
7. Wallington LA, Durham J, Bunce CM, Drayson MT, Brown G. Triiodothyronine blocks potentiation of HL60 monocyte differentiation by anti-inflammatory agents and by steroids and induces apoptosis of all-trans retinoic acid "primed" cells. Leuk Res 1997;21:623-634
8. Bunce CM, Mountford JC, French PJ, et al. Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketo-reductase family. Biochim Biophys Acta 1996;1311:189-198 (Pubitemid 26186131)
9. Desmond JC, Mountford JC, Drayson MT, et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res 2003;63:505-512 (Pubitemid 36152514)
10. Birtwistle J, Hayden RE, Khanim FL, et al. The aldoketo reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4 dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutation Res 2009;662:67-74.
11. Fung KM, Samara EN, Wong C, et al. Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006;13:169-180
12. Vihko P, Herrala A, Harkonen P, et al. Enzymes as modulators in malignant transformation. J Steroid Biochem Mol Biol 2005;93:277-283 (Pubitemid 40602501)
13. Ji Q, Chang L, Stanczyk FZ, Ookhtens M, Sherrod A, Stolz A. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a prereceptor regulator of androgen receptor signaling. Cancer Res 2007;67:1361-1369 (Pubitemid 46270797)
14. Hsu NY, Ho HC, Chow KC, et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 2001;61:2727-2731 (Pubitemid 32685861)
15. Tai HL, Lin TS, Huang HH, et al. Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. Oncol Rep 2007;17:305-311
16. Day JM, Tutill HJ, Purohit A, Reed MJ. Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 2008;15:665-692
17. Penning TM, Steckelbroeck S, Bauman DR, et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006;248:182-191
18. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 2008;75:484-493 (Pubitemid 350298472)
19. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, White SA. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res 2004;64:1802-1810.
20. Bydal P, Luu-The V, Labrie F, Poirier D. Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem 2009;44:632-644
21. Gobec S, Brozic P, Rizner TL. Nonsteroidal antiinflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents. Bioorg Med Chem Lett 2005;15:5170-5175 (Pubitemid 41463641)
22. Cragg GM, Newman DJ. Plants as a source of anticancer agents. J Ethnopharmacol 2005;100:72-79
23. Folkes LK, Wardman P. Oxidative activation of indole-3-acetic acids to cytotoxic species - a potential new role for plant auxins in cancer therapy. Biochem Pharmacol 2001;61:129-136 (Pubitemid 32121777)
24. Ishii Y, Hori Y, Sakai S, Honma Y. Control of differentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant redifferentiation-inducing hormones. Cell Growth Differ 2002;13:19-26. (Pubitemid 34106796)
25. Fingrut O, Flescher E. Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 2002;16:608-616 (Pubitemid 34449741)
26. Flescher E. Jasmonates in cancer therapy. Cancer Lett 2007;245:1-10. (Pubitemid 44959368)
27. Wasternack C. Jasmonates: an update on biosynthesis, signal transduction and action in plant stress response, growth and development. Ann Bot (Lond) 2007;100:681-697 (Pubitemid 47511777)
28. Heyfets A, Flescher E. Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy- D-glucose. Cancer Lett 2007;250:300-310 (Pubitemid 46529453)
29. Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 2005;65:1984-1993 (Pubitemid 40478628)
30. Oh SY, Kim JH, Park MJ, et al. Induction of heat shock protein 72 in C6glioma cells by methyl jasmonate through ROS-dependent heat shock factor 1 activation. Int J Mol Med 2005;16:833-839
31. Matsuura K, Shiraishi H, Hara A, et al. Identification of a principal mRNA species for human 3α-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem 1998;124:940-946 (Pubitemid 28544904)
32. Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-activated receptor γ inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J Dig Dis 2007;8:82-88 (Pubitemid 46773619)
33. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol 2002;103:22-33. (Pubitemid 34478417)
34. Ray DM, Akbiyik F, Phipps RP. The peroxisome proliferator-activated receptor γ (PPARγ) ligands 15-deoxy-Δ12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARγ-independent mechanisms. J Immunol 2006;177:5068-5076 (Pubitemid 44527577)
35. Straus DS, Pascual G, Li M, et al. 15-Deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci U S A 2000;97:4844-4849 (Pubitemid 30238645)
36. Hayden RE, Pratt G, Davies NJ, et al. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dΔ(12,14,)PGJ(2). Leukemia 2009;23:292-304.
37. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977;270:347-349
38. Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW. An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1). Blood 1980;56:265-273 (Pubitemid 10043428)
39. Koeffler HP, Golde DW. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 1978;200:1153-1154 (Pubitemid 9087500)
40. Goetz ME, Luch A. Reactive species: a cell damaging rout assisting to chemical carcinogens. Cancer Lett 2008;266:73-83.
41. Trachootham D, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer cell 2006;10:241-252 (Pubitemid 44311067)
42. Fruehauf JP, Meyskens FL, Jr. Reactive oxygen species: a breath of life or death? Clin Cancer Res 2007;13:789-794
43. Ishii Y, Kiyota H, Sakai S, Honma Y. Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. Leukemia 2004;18:1413-1419 (Pubitemid 39136752)
44. Fingrut O, Reischer D, Rotem R, et al. Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells. Br J Pharmacol 2005;146:800-808 (Pubitemid 41622246)
45. Goldin N, Arzoine L, Heyfets A, et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 2008;27:4636-4643
46. Goldin N, Heyfets A, Reischer D, Flescher E. Mitochondria-mediated ATP depletion by anti-cancer agents of the jasmonate family. J Bioenerg Biomembr 2007;39:51-57 (Pubitemid 46877174)
47. Takahashi F, Yoshida R, Ichimura K, et al. The mitogen-activated protein kinase cascade MKK3-MPK6 is an important part of the jasmonate signal transduction pathway in Arabidopsis. Plant Cell 2007;19:805-818 (Pubitemid 46953229)
48. Traore K, Sharma R, Thimmulappa RK, Watson WH, Biswal S, Trush MA. Redox-regulation of Erk1/2-directed phosphatase by reactive oxygen species: role in signaling TPA-induced growth arrest in ML-1 cells. J Cell Physiol 2008;216:276-285
49. Ohara H, Miyabe Y, Deyashiki Y, Matsuura K, Hara A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 1995;50:221-227